Metabolic Disposition and Pharmacokinetics of [14C]‐Amprenavir, a Human Immunodeficiency Virus Type 1 (HIV‐1) Protease Inhibitor, Administered As a Single Oral Dose to Healthy Male Subjects

MLA

Sadler, Brian M., et al. “Metabolic Disposition and Pharmacokinetics of [14C]‐Amprenavir, a Human Immunodeficiency Virus Type 1 (HIV‐1) Protease Inhibitor, Administered As a Single Oral Dose to Healthy Male Subjects.” Journal of Clinical Pharmacology, vol. 41, no. 4, Apr. 2001, pp. 386–96. EBSCOhost, https://doi.org/10.1177/00912700122010249.

APA

Sadler, B. M., Chittick, G. E., Polk, R. E., Slain, D., Kerkering, T. M., Studenberg, S. D., Lou, Y., Moore, K. H. P., Woolley, J. L., & Stein, D. S. (2001). Metabolic Disposition and Pharmacokinetics of [14C]‐Amprenavir, a Human Immunodeficiency Virus Type 1 (HIV‐1) Protease Inhibitor, Administered As a Single Oral Dose to Healthy Male Subjects. Journal of Clinical Pharmacology, 41(4), 386–396. https://doi.org/10.1177/00912700122010249

Chicago

Sadler, Brian M., Gregory E. Chittick, Ronald E. Polk, Douglas Slain, Thomas M. Kerkering, Scott D. Studenberg, Yu Lou, Katy H. P. Moore, Joseph L. Woolley, and Daniel S. Stein. 2001. “Metabolic Disposition and Pharmacokinetics of [14C]‐Amprenavir, a Human Immunodeficiency Virus Type 1 (HIV‐1) Protease Inhibitor, Administered As a Single Oral Dose to Healthy Male Subjects.” Journal of Clinical Pharmacology 41 (4): 386–96. doi:10.1177/00912700122010249.